張浤榮張兆祥廖俊厚王紹全Shao-Chuan Wang醫學研究所2026-10-299999-12-312017https://handle.ncl.edu.tw/11296/c9u6pyhttps://scholars.csmu.edu.tw/handle/123456789/36283各國間死亡對發病比(MIR; Mortality-To-Incidence Ratio) 的差異,可反映臨床的結果及大腸直腸癌治療的干與措施。我們針對兩種常見泌尿道癌症-前列腺癌及膀胱癌,研究其死亡對發病比與各國間癌症照護差距的關聯。本研究中的癌症發病率和死亡率是從GLOBOCAN 2012數據資料庫所獲得,世界衛生組織國家排名(WHO ranking) 和健康總支出佔國民生產毛額比(Total expenditure of health (e)/GDP) 是由世界衛生組織所取得,併透過線性回歸分析來分析變量之間的相關性。經發病例數及資料品質篩選後,分別有35 (前列腺癌) 及 33 (膀胱癌) 個國家可供分析。兩種癌症全球的粗發病率、死亡率、死亡對發病比分別為: 前列腺癌30.8 (每100,000人) 8.6, 28.1;膀胱癌 6.1, 2.3,0.38。正如我們所預期,在歐洲和美洲以及較高開發地區,觀察到的兩種癌症發病率和死亡率較高; 反之,較低開發地區的死亡對發病比則較高 (前列腺癌差2.5倍)。根據國家間的分析顯示,美國 (前列腺癌13.0) 與德國 (膀胱癌0.19) 擁有最低的死亡對發病比。在膀胱癌的高相對死亡對發病比 (relative MIR; female MIR/male MIR) 則凸顯出健康照護上性別差異。關於死亡對發病比與癌症照護差距之間的關聯,世界衛生組織排名良好,及健康總支出/國內生產毛額比高的國家,其與低死亡對發病比有顯著相關(前列腺癌: p<0.001; 膀胱癌: WHO ranking p=0.05, e/GDP p=0.004)。我們的研究結果證實,這兩種常見泌尿道癌症其死亡對發病比的變異,與各國間的癌症照護差距息息相關,進一步支持了癌症照護差距在臨床結果的重要角色。The variation in mortality-to-incidence ratio (MIR) among countries reflects the clinical outcomes and the available interventions for colorectal cancer treatments. We evaluate the association between MIR and cancer care disparities among countries in two common urinary tract malignancies – prostate cancer and urinary bladder cancer, which is rarely investigated issue before. For the present study, cancer incidence and mortality rates were obtained from the GLOBOCAN 2012 database. The WHO rankings and ratio of total expenditures on health in gross domestic product (e/GDP) in various countries were obtained from the World Health Organization. The association between variables was analyzed by linear regression analyses. According to new case numbers and data quality, 35 (prostate cancer) and 33 (urinary bladder cancer) countries were included for analysis. The world rude incidence, mortality, and MIRs were prostate cancer: 30.8 (/100,000), 8.6, 28.1; urinary bladder cancer 6.1, 2.3, 0.38, in orders. As expected, high cancer incidence and mortality rates were observed in more developed regions, such as Europe and the America. However, the MIR were higher in the less developed regions (2.5 times higher in prostate cancer). Analysis according to countries revealed United States of America (prostate cancer 13.0) and Germany (urinary bladder 0.19) to have the lowest MIR. Besides, high relative MIR (rMIR; female MIR/male MIR) for bladder cancer were noted in many developed countries, which emphasized the gender difference in health care system. Regarding the association between MIR and cancer care disparities, countries with good WHO ranking and high e/GDP were significantly correlated with low MIR (prostate cancer: p<0.001; urinary bladder cancer: WHO ranking p=0.05, e/GDP p=0.004)。Our study demonstrated the MIR variation for these two cancers correlates with cancer care disparities among countries and further supports the role of cancer care disparities in clinical outcomes.前列腺癌膀胱癌死亡率發病率死亡對發病比相對死亡對發病比性別差異世界衛生組織排名Prostate cancerurinary bladder cancermortality-to-incidence ratiogender differenceWHO ranking分析前列腺癌與膀胱癌之死亡對發病比與各國健康照護差距之相關thesis